John L. Brottem, General Counsel of Alamar Biosciences, Inc. (NASDAQ:ALMR), filed a Form 4 on September 16, 2026, reporting the acquisition of 29,000 restricted stock units and an employee stock option covering 85,000 shares of common stock, both transacted on September 14, 2026.

Key Highlights

  • RSU Award: Brottem acquired 29,000 restricted stock units on September 14, 2026, at a price of $0, resulting in direct beneficial ownership of 29,000 shares of common stock following the transaction.
  • Stock Option Grant: An employee stock option (right to buy) covering 85,000 shares of common stock was acquired on September 14, 2026, with an exercise price of $27.99 and an expiration date of September 13, 2036.
  • RSU Vesting Schedule: One-quarter of the RSUs will vest on November 21, 2027, with the remainder vesting in twelve equal quarterly installments thereafter, subject to continuous service.
  • Option Vesting Schedule: One-quarter of the option shares will vest on September 14, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to continuous service.
  • Reporting Person Role: Brottem is identified as an officer of Alamar Biosciences, serving as General Counsel.
  • Ownership Form: Both the RSU award and the stock option are held directly by the reporting person.

Brottem's Equity Grants at Alamar Biosciences: RSUs and Options Reported

According to the Form 4 filed with the U.S. Securities and Exchange Commission, John L. Brottem, General Counsel of Alamar Biosciences, Inc., reported two equity award transactions dated September 14, 2026. The first was an acquisition of 29,000 restricted stock units classified under transaction code "A," at a price of $0. Following this transaction, the filing states Brottem directly and beneficially owns 29,000 shares of common stock.

The filing also discloses an employee stock option granting Brottem the right to buy 85,000 shares of Alamar Biosciences common stock at an exercise price of $27.99 per share. The option was also acquired on September 14, 2026, at a price of $0, and is set to expire on September 13, 2036. Following this transaction, the filing reports Brottem directly and beneficially owns 85,000 derivative securities of this type.

Per the explanations included in the filing, the RSU vesting schedule provides that one-quarter of the RSUs will vest on November 21, 2027, with the remaining RSUs vesting in twelve equal quarterly installments thereafter, contingent on the reporting person's continuous service at each vesting date. For the stock option, one-quarter of the total shares subject to the option will vest on September 14, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter, also subject to continuous service. The form was filed by Timothy White as Attorney-in-Fact on September 16, 2026.

What Was Disclosed

Alamar Biosciences General Counsel John L. Brottem reported receiving 29,000 RSUs and a stock option covering 85,000 shares at $27.99 per share, both dated September 14, 2026, with multi-year vesting schedules tied to continuous service.